Летонија - Летонски - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - lenalidomīds - kapsula, cietā - 10 mg

Летонија - Летонски - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - lenalidomīds - kapsula, cietā - 15 mg

Летонија - Летонски - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - lenalidomīds - kapsula, cietā - 20 mg

Летонија - Летонски - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - lenalidomīds - kapsula, cietā - 25 mg

Европска Унија - Летонски - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - multiple mieloma - antineoplastiski līdzekļi - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Летонија - Летонски - Zāļu valsts aģentūra

stada arzneimittel ag, germany - brinzolamidum, timololum - acu pilieni, suspensija - 10 mg/5 mg/ml

Летонија - Летонски - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - brinzolamidum, timololum - acu pilieni, suspensija - 10 mg/ml/5 mg/ml

Европска Унија - Летонски - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - prekursoru šūnu limfoblastiska leikēmija-limfoma - antineoplastiski līdzekļi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Европска Унија - Летонски - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinibs - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Летонија - Летонски - Zāļu valsts aģentūra

novartis baltics, sia, latvia - ciklosporīns - kapsula, mīkstā - 100 mg